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The  mechanism  of  epithelial  regeneration 
varies among organs. In the skin and intestine, 
niches for resident stem cells ensure rapid re-
newal of epithelial cell populations upon tissue 
injury (Blanpain et al., 2004; Barker and Clevers, 
2007). In the liver, pancreas, and lungs, epithe-
lial cells have a relatively slow renewal capacity 
(Dor  et  al.,  2004;  Erker  and  Grompe,  2008; 
Stripp, 2008). Populations of functionally dif-
ferentiated cells termed facultative progenitor 
cells can be activated upon injury to enter the 
cell cycle and give rise to epithelial cells (Dor   
et al., 2004; Erker and Grompe, 2008). In the 
airway epithelium, specific cells act as progeni-
tor cells to repair different regions of airways. 
Clara cells of upper airways normally function 
to secrete mucus but also play a role in the re-
pair (Rawlins and Hogan, 2006; Stripp, 2008; 
Rawlins et al., 2009a). The lung alveolar epi-
thelium is composed of type I cells that make 
up 95% of the alveolar surface area and type II 
cells making up the remainder (Mason, 2006). 
Upon  alveolar  epithelial  injury,  differentiated 
type II cells are activated to induce epithelial 
barrier repair (Rawlins and Hogan, 2006; Stripp, 
2008). These cells upon entering the cell cycle 
give rise to both type II and type I cells (Mason, 
2006; Rawlins and Hogan, 2006; Sugahara et al., 
2006; Stripp, 2008). Studies using NO3 to injure 
alveoli showed that 3H first labeled proliferating 
type II cells and later type I cells (Evans et al., 
1973, 1975). Cultured type II cells were also 
shown to trans-differentiate directly into type I 
cells (Dobbs, 1990; Paine and Simon, 1996).
Alveolar  epithelial  injury  responsible  for 
the acute respiratory distress syndrome occurs 
secondary to the release of proinflammatory 
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The alveolar epithelium is composed of the flat type I cells comprising 95% of the  
gas-exchange surface area and cuboidal type II cells comprising the rest. Type II cells are 
described as facultative progenitor cells based on their ability to proliferate and  
trans-differentiate into type I cells. In this study, we observed that pneumonia induced by 
intratracheal instillation of Pseudomonas aeruginosa (PA) in mice increased the expression 
of the forkhead transcription factor FoxM1 in type II cells coincidentally with the induction 
of alveolar epithelial barrier repair. FoxM1 was preferentially expressed in the Sca-1+ 
subpopulation of progenitor type II cells. In mice lacking FoxM1 specifically in type II cells, 
type II cells showed decreased proliferation and impaired trans-differentiation into type I 
cells. Lungs of these mice also displayed defective alveolar barrier repair after injury.  
Expression of FoxM1 in the knockout mouse lungs partially rescued the defective trans-
differentiation phenotype. Thus, expression of FoxM1 in type II cells is essential for their 
proliferation and transition into type I cells and for restoring alveolar barrier homeostasis 
after PA-induced lung injury.
© 2011 Liu et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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RESULTS
FoxM1 expression in type II cells during alveolar epithelial 
repair after PA exposure
To study mechanisms of alveolar epithelial repair, we used an 
established mouse airspace injury model generated by intra-
tracheal (i.t.) injection of PA (strain 103; Sadikot et al., 2006). 
Death of alveolar epithelial cells was observed at 24 h after 
infection (Fig. S1, A–C). Acute lung inflammation and in-
creased cell density were observed at 48–96 h after PA challenge, 
and the most severe changes were seen at 72 h (Fig. 1, A–F). 
At 7 d after infection, normal airspace morphology was re-
stored (Fig. 1 F). A previous study showed that the maximum 
inflammatory response occurred at 24–48 h in PA-treated 
mice (Sadikot et al., 2006); thus, the increased number of cells 
at 72 and 96 h may reflect cell proliferation occurring during 
the repair phase. Using BrdU labeling to identify proliferating 
cells, we observed that the number of BrdU+ cells was sig-
nificantly increased at 72 h after infection (Fig. S1, D and E), 
indicating that the lungs are actively engaged in repair at this 
time. By double labeling with antibodies against BrdU and 
type II cell marker Sp-C (for surfactant-associated protein 
[SAP] C; Wert et al., 1993), we found that the type II cell prolif-
eration rate was significantly increased at 72 h, which is the 
beginning of the repair phase (Fig. 1, G–I). These results support 
the concept that a type II cell can function as a progenitor cell 
during alveolar repair (Mason, 2006; Sugahara et al., 2006).
Type II cells were isolated after PA infection, and RNA 
was prepared for real-time RT-PCR analysis. FoxM1 tran-
script amounts started to increase at 48 h, peaked at 72 h, and 
decreased at 96 h (Fig. 2 A). In contrast, type II cell expression 
of several other genes, Sp-C (Wert et al., 1993), CC10 (Rawlins 
et al., 2009a), Gata6 (Zhang et al., 
2008),  Id2  (Liu  and  Hogan,  2002; 
Rawlins et al., 2009b), Elf5 (Metzger 
et al., 2008), Erm (Liu et al., 2003), and 
E-cadherin  (Reddy  et  al.,  2004),  did 
cytokines as well as proteases and oxidants (Ware and Matthay, 
2000). However, little is known about the transcriptional 
machinery directing the alveolar repair program. FoxM1 (or 
foxm1b), a member of the mammalian forkhead box family 
of transcription factors, upon activation induces G1/S transi-
tion by decreasing the expression of nuclear cyclin-dependent 
kinase inhibitor proteins p27kip and p21Cip (Costa et al., 
2005). FoxM1 also induces expression of genes essential for 
G2/M phase of the cell cycle, CDC25b, cyclin B1, Polo-like 
kinase 1, and Aurora B kinase (Costa et al., 2005). Based on 
the role of FoxM1 in mediating morphogenesis and differ-
entiation of the embryonic lung (Kim et al., 2005a; Kalin   
et al., 2008) and in repairing the lung endothelial barrier 
after LPS-induced injury (Zhao et al., 2006), in this study, we 
addressed the function of FoxM1 in the mechanism of alveolar 
epithelial barrier repair.
Using the Pseudomonas aeruginosa (PA) model of lung   
alveolar injury (Gray and Kreger, 1979; Sadikot et al., 2006), 
we found that FoxM1 expression in type II cells after PA chal-
lenge was coupled to increased type II cell proliferation and 
reannealing of the alveolar epithelial barrier. FoxM1 was also 
preferentially expressed in the Sca-1+ (for stem cell antigen 1; 
Holmes and Stanford, 2007) progenitor subfraction of type II 
cells. Inactivation of FoxM1 in type II alveolar cells in mice 
prevented type II cell proliferation and their trans-differentiation 
into type I cells, resulting in prolonged alveolar barrier dys-
function. In a rescue experiment, expression of FoxM1 in the 
knockout mice partially restored the trans-differentiation de-
fect. Thus, FoxM1 is required for the progenitor cell function 
of type II epithelial cells and repairing of the alveolar epithe-
lial barrier after PA-induced lung injury.
Figure 1.  Morphology and cell  
proliferation after PA-induced lung injury.  
(A–F) Lung sections were prepared for control 
(CON; A) and at 24 h (B), 48 h (C), 72 h (D),  
96 h (E), and 7 d (F) after i.t. injection of PA and 
processed for H&E staining. (G and H) BrdU 
and Sp-C double labeling of control lungs  
(G) and lungs at 72 h after PA injection (H). 
DAPI was used to show nuclei. Arrows denote 
proliferative type II cells (double positive for 
Sp-C and BrdU). Results are representative of 
similar observations from three independent 
experiments. Bars: (A–F) 60 µm; (G and H)  
20 µm. (I) Percentage of BrdU+Sp-C+ cells 
among the Sp-C+ cells in noninfected (Basal) 
and 72-h-postinfected lungs. Data are pre-
sented as mean ± SE (*, P < 0.05 vs. control). 
More than 500 cells were scored in each sam-
ple (n = 5 mice for each group from three 
independent experiments).JEM Vol. 208, No. 7 
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is activated in alveolar type II cells by the doxycycline-inducible 
rtTA/TetO system coupled with type II cell–specific promoter 
SPC (Perl et al., 2002; Kalin et al., 2008). Cre mediates dis-
ruption of FoxM1 in type II cells through the loxP sites flank-
ing exons 4–7 of the FoxM1 gene that encode the DNA 
binding and transcriptional activation domains (Fig. 4 A; 
Kalin et al., 2008). This doxycycline-inducible system enabled   
selective disruption of FoxM1 in type II cells of adult lungs.
not show clear changes at 72 h after infection (Fig. S2). Im-
portantly, expression of FoxM1 in type I cells did not increase 
at 72 h after infection (Fig. 2 B). Thus, the expression of 
FoxM1 increased specially and significantly only in type II cells 
during the repair phase.
FoxM1 is preferentially expressed in the Sca-1+ subgroup  
of type II cells
Because the type II cell subpopulation may function as facul-
tative progenitor cells during alveolar repair, we determined 
whether the FoxM1-expressing type II cells concomitantly 
expressed Sca-1, a marker of progenitor cells (Holmes and 
Stanford, 2007). Sca-1 was analyzed by FACS in freshly 
isolated type II cells before and at 72 h after infection using 
PE-labeled rat anti–Sca-1 mAb (Raiser and Kim, 2009). Few 
Sca-1+ type II cells were present in control lungs, whereas 
Sca-1+ cell number increased significantly at 72 h after PA 
(Fig. 3, A and B); the percentage of Sca-1+ cells in type II cells 
was as high as 60%. Notably, most Sca-1+ cells also expressed 
the type II cell marker Sp-C (Fig. 3 C). Furthermore, most of 
the Sca-1+ cells showed positive staining for epithelial cell 
markers E-cadherin and pan-cytokeratin (Fig. 3, D and E; 
Willis et al., 2005), indicating that these were epithelial cells. 
To determine whether FoxM1 was preferentially expressed 
in Sca-1+ type II cells, real-time RT-PCR analysis of Sca-1+ 
and Sca-1 type II cells isolated at 72 h after PA showed that 
the Sca-1+ subpopulation of type II cells expressed greater 
FoxM1 transcript than the Sca-1 type II cells (Fig. 3 G). 
Thus, FoxM1 was preferentially expressed in the activated 
subpopulation of type II cells, and timing of its expression was 
coincident with its postulated role in the mechanism of alve-
olar epithelial barrier repair.
Type II cell–specific deletion of FoxM1 in mice
To address the role of FoxM1 expressed in type II cells in me-
diating alveolar epithelial barrier repair, we used SPC-rtTA/
TetO-Cre/FOXM1EKO  mouse  line  to  disrupt  the  FoxM1 
gene specifically in type II cells. Expression of Cre recombinase 
Figure 2.  Time course of FoxM1 expression in PA-challenged lungs. 
(A and B) Expression of FoxM1 mRNA was evaluated by real-time RT-PCR in 
type I (B) and type II (A) cells before (basal) or at the indicted times after PA 
infection. Data are presented as mean ± SE (n = 3–5 mice for each group 
from three independent experiments; *, P < 0.05 vs. control).
Figure 3.  FoxM1 transcript is enriched in Sca-1+ type II cells early 
during the repair phase. (A) FACS analyses show the percentage of Sca-1+ 
cells among type II cells before (non-PA) or 72 h after PA infection. Data are 
representative of more than five similar independent observations. (B) Per-
centage of Sca-1+ cells in type II cells before and after PA challenge. Data are 
presented as mean ± SE (n = 9, more than five independent experiments;  
*, P < 0.05 vs. control). (C) FACS analysis showing Sca-1 and Sp-C expression 
on type II cells appearing at 72 h after PA infection. (A and C) Cells were gated   
on forward and side scatter to exclude debris and cell clusters. Numbers indi-
cate the percentage of cells positive for the indicated marker out of total type II  
cells. (D and E) Expression of E-cadherin (E-Cad; D) and keratin (E) on Sca-1+ 
type II cells. Bar, 10 µm. (C–E) Results are representative of three similar inde-
pendent observations. (F) Relative expression of Sca-1 mRNA in type II cells 
before (basal) or 72 h after PA infection as evaluated by real-time RT-PCR.  
(G) Relative expression level of FoxM1 in Sca-1+ and Sca-1 type II cells was 
evaluated by RT-PCR. (F and G) Data are presented as mean ± SE (n = 5 in 
three independent experiments; *, P < 0.05 vs. control).1476 FoxM1 facilitates repair of alveolar injury | Liu et al.
had lost their Sp-C expression and were actively engaged in 
repair at 72 h after PA challenge. In addition, we observed that 
at 72 h after PA, >70% of Sca-1+ cells were YFP+ (Fig. 4 H), 
which is consistent with the notion that these cells were de-
rived from the Sp-C–expressing cells.
Mutant (SPC-rtTA/TetO-Cre/FOXM1EKO) mice were fed 
doxycycline for 2 wk to induce type II cell–specific disruption of 
FoxM1. Littermates with genotype +/TetO-Cre/FOXM1EKO 
were used as WT controls. In control mice lacking the SPC-rtTA 
transgene, Cre was not expressed and FoxM1 was not disrupted. 
Mutant mice without PA challenge did not show any overt 
changes in behavior and lifespan. Type II cells were isolated and 
subjected to real-time RT-PCR analysis to assess messenger 
RNA (mRNA) expression of FoxM1. In noninfected lungs, 
FoxM1 mRNA levels in mutant and WT cells were similar, 
which is likely the result of the 2–3-wk turnover rate of normal 
type II cells (Mason, 2006) and because FoxM1 transcript is   
being produced before doxycycline administration. However, at 
72 h after PA challenge, the amount of FoxM1 mRNA in mu-
tant type II cells was significantly lower than control (Fig. 4 I), 
indicating a marked disruption of FoxM1 expression.
Decreased type II cell proliferation in FoxM1  
mutant lungs
We compared type II cell proliferation in control and 
mutant lungs by double labeling with antibodies to BrdU 
and Sp-C after PA-mediated injury. Lungs were isolated 
at 72 h after PA, and BrdU was injected at 5 h before lung 
isolation. We observed that the number of BrdU+Sp-C+ 
proliferating type II cells in mutant mice was significantly 
reduced even though the cells surrounding small blood ves-
sels were proliferating at a similar rate as WT (Fig. 5, A–D). 
The efficiency of inducible tissue-specific deletion was 
evaluated using the SPC-rtTA/TetO-Cre/ROSA-YFP mouse 
line (designated ROSA-YFP), in which the stop sequence 
flanked by two loxP sites is located at the ROSA-YFP locus to 
disrupt YFP expression. When Cre expression was induced 
through doxycycline, the stop sequence was deleted to enable 
YFP expression in type II cells as well as their progenies 
(Rawlins et al., 2009a). By antibody staining of lungs from 
mice fed doxycycline, we observed that >70% of the 800 
Sp-C+ cells from three mice were  YFP+, indicating a recombina-
tion frequency of 70% (Fig. 4, B–D). YFP expression in type II 
cells was doxycycline dependent because only 10% of type II 
cells expressed YFP in its absence (Fig. S3 A). In addition, >90% 
(total 420 cells from three mice; >100 cells from each mice 
were counted) of the cuboidal YFP+ cells in alveoli were 
Sp-C+ when mice were not challenged with PA (Fig. 4, B–D). 
In contrast, at 72 h after PA, YFP+Sp-C cuboidal cells were 
frequently observed (Fig. 4, E–G). Some of these cells were 
proliferating as shown by their BrdU labeling (Fig. S3, C and D), 
and some YFP+Sp-C cells expressed the type I cell marker 
T1 (Fig. S3, E and F). These results indicate that type II cells 
Figure 4.  Type II cell–specific disruption of FoxM1 in mice. 
(A) An inducible type II cell–specific deletion system. rtTA protein is 
produced from type II cell–specific Sp-C promoter. After interacting 
with doxycycline, rtTA activates TetO-CMV promoter to produce Cre 
recombinase, which binds to the loxP sites and induces type II cell–
specific recombination. (B–G) A ROSA-YFP line was used to show 
type II cell–specific recombination. Cells with Cre-induced recombi-
nation showed YFP expression. (B–D) ROSA-YFP lung without PA 
injection (Non-inj). The staining of YFP (B), Sp-C (C), and merge (D) 
are shown for the same section. (E–G) ROSA-YFP lung at 72 h after 
PA injection. The localization of YFP (E), Sp-C (F), and merge (G) are 
shown for one section. Note that some of the YFP+ cuboidal cells are 
Sp-C (arrows). Bar, 20 µm. (H) FACS analysis showing expression of 
Sca-1 and YFP in type II cells at 72 h after PA injection. Cells were 
gated on forward and side scatter to exclude debris and cell clusters. 
Numbers indicate the percentage of cells positive for the indicated 
marker out of total type II cells. Data are representative of three 
independent experiments. (I) Adult mice with genotype SPC-rtTA/
TetO-Cre/FOXM1EKO or +/TetO-Cre/FOXM1EKO were fed with doxy-
cycline for 2 wk, and lungs were then challenged with PA. FoxM1 
expression in type II cells before (Non-inj) or 72 h after PA challenge 
was assayed by real-time RT-PCR. Data are presented by mean ± SE 
(n = 3–5 mice for each group from three independent experiments; 
*, P < 0.05 vs. control).JEM Vol. 208, No. 7 
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YFP+ cells were BrdU+ (Fig. 5 F). Thus, in the same lung, the 
proliferation rate of WT type II cells was double that of 
FoxM1-deleted type II cells.
CDC25C and cyclin B1, two critical factors required for 
cell cycle progression, are regulated by FoxM1 in endothe-
lial cells (Zhao et al., 2006). To test their role in mediating 
type II cell proliferation, real-time RT-PCR analysis was per-
formed in type II cells isolated at 72 h after infection. We ob-
served that mRNA levels of both CDC25C and cyclin B1 
were significantly decreased in FoxM1-deleted cells compared 
with control (Fig. 5, G and H). Thus, the decreased expression 
of CDC25C and cyclin B1 may contribute to the proliferation-
defective phenotype of FoxM1-deficient type II cells seen 
during alveolar repair.
To determine whether overexpressing FoxM1 can drive 
type II cell proliferation, we infected cultured WT non–PA-
treated type II cells with adenoviral vector expressing FoxM1 
(Wang et al., 2002) or a control viral vector. When cultured 
with  BrdU,  FoxM1-expressing  virus–infected 
cells show significantly greater BrdU incorpo-
ration than control cells (Fig. 5, I and J).
Defective type I cell trans-differentiation in 
FoxM1-deficient type II cells and impaired 
alveolar epithelial barrier recovery in mice
Because type II cells are believed to trans- 
differentiate into type I cells during alveolar repair 
For each mouse, we randomly selected 10 areas in the lung 
periphery to score proliferating type II cells. In control mice, 
6.8 ± 0.9% of Sp-C+ cells were BrdU+, whereas only 2.7 ± 
1.3% of Sp-C+ cells in the mutant were BrdU+ (mean ± SE; 
n = 3 mice; Fig. 5 E). Thus, FoxM1 disruption in type II cells 
markedly reduced proliferation of these cells during the phase 
of alveolar repair after PA insult.
We  also  used  the  SPC-rtTA/TetO-Cre/ROSA-YFP/ 
FOXM1EKO (ROSA-YFP-EKO) mouse line to compare cell 
proliferation in FoxM1+ and FoxM1 type II cells of the same 
mouse lung. In this line, YFP+ type II cells are expected to 
have Cre expression, and most of them have disrupted FoxM1, 
whereas most YFP type II cells are without Cre and have 
WT FoxM1. Type II cells were isolated from ROSA-YFP-
EKO mice and labeled with BrdU for 24 h. YFP+ and YFP 
cells were separated either by MoFlo fluorescent cell sorting 
or visually identified based on antibody staining against YFP. 
We found that 8% of  YFP cells were BrdU+, whereas 4% of 
Figure 5.  Defective type II cell proliferation in 
mouse lungs having FoxM1 deleted in type II cells. 
(A and B) Double labeling of BrdU and Sp-C in WT (A) 
and mutant (Mut; SPC-rtTA/TetO-Cre/FOXM1EKO;  
B) lungs at 72 h after infection. Small blood vessels are 
indicated by thin white lines (B) or the circled area (A).  
(C and D) Higher magnification images of the blue rect-
angles in A and B, respectively. Arrow shows BrdU colocal-
ization with Sp-C in a WT cell. Data are representative of 
three independent experiments. (E) Percentage of 
BrdU+Sp-C+ cells among Sp-C+ cells in WT and mutant at 
72 h after infection. (F) Type II cells were isolated from 
ROSA-YFP-EKO mice. YFP+ and YFP cells were separated 
and labeled with BrdU for 24 h. The percentage of BrdU+ 
cells among YFP+ (mutant) or YFP (WT) type II cells were 
compared. (E and F) Data are presented as mean ± SE  
(*, P < 0.05 vs. control). 100–500 type II cells were scored 
in each sample (n = 3 mice for each group from three 
independent experiments). (G and H) Relative expression 
of CDC25C (G) and CyclinB1 (H) in uninfected WT cells 
(basal) and in WT (Con) and FoxM1/ type II cells at  
72 h after PA infection as assessed by real-time RT-PCR. 
Data are presented as mean ± SE (n = 3–4 mice for each 
group from three independent experiments; *, P < 0.05 
vs. control). (I and J) Isolated WT, non–PA-treated type II 
cells cultured with BrdU were infected with control  
adenovirus (Con adv; I) or adenovirus expressing FoxM1 
(FoxM1 adv; J). Data are representative of three indepen-
dent experiments. Bars: (A and B) 60 µm; (C and D)  
25 µm; (I and J) 20 µm.1478 FoxM1 facilitates repair of alveolar injury | Liu et al.
Many of these cells appeared to have higher YFP expression 
than the Sp-C+ cells (Fig. 6, G and H), perhaps reflecting a 
higher metabolic rate of the activated type II cells than con-
trol cells. However, in ROSA-YFP-EKO lungs, we did not 
observe any cuboidal YFP+ cell clusters, and most (>90%; 
three mice, 100–500 cells from each mouse were scored) of 
the YFP+ cuboidal cells expressed Sp-C and not T1 (Fig. 6, 
K  and  L).  Because  in  ROSA-YFP-EKO  lungs  FoxM1- 
mediated proliferation was disrupted only in type II cells, 
these findings demonstrate that the cuboidal YFP+Sp-C cell 
clusters observed in the control were derived from type II 
cells; thus, these cells were undergoing trans-differentiation 
into type I cells. Moreover, the mutant type II cells, although 
defective in proliferation, were also defective in type I cell 
trans-differentiation.
(Evans et al., 1973, 1975), next we addressed whether disrupt-
ing FoxM1 in type II cells resulted in a decreased number 
of type I cells and thereby led to impaired recovery of al-
veolar epithelial barrier function. First, we used SPC-rtTA/
TetO-Cre/ROSA-YFP/+  (ROSA-YFP)  and  SPC-rtTA/
TetO-Cre/ROSA-YFP/FOXM1EKO (ROSA-YFP-EKO) mouse   
lines to follow the fate of YFP+ cells after injury. In both 
lines, most (>90%; for each genotype, 300–400 cells from two 
to three mice were scored) of the cuboidal YFP+ cells ex-
pressed the type II cell marker Sp-C in the absence of injury 
(Fig. 6, A, B, and I–J). At 5 d after infection, YFP+Sp-C cu-
boidal cells were frequently observed in ROSA-YFP lungs. 
Some of these cells formed clusters and expressed the type I 
cell marker T1 (Chen et al., 2004), and many of these cells 
were negative for type II cell marker Sp-C (Fig. 6, C–F). 
Figure 6.  Defective activation and trans-differentiation of FoxM1-deficient type II cells in vivo. (A–L) WT (ROSA-YFP) and mutant (ROSA- 
YFP-EKO) lungs were compared in the noninfected (Non-inj; A, B, I, and J) and 5 d after PA infection groups (C–H, K, and L). (A–H) Lungs from control  
(ROSA-YFP) mice. (I–L) Lungs from mutant (ROSA-YFP-EKO) mice. A, C, I, and K were labeled with type I cell marker T1 and YFP, whereas B, D, J, and  
L are the same section as in A, C, I, and K, respectively, but labeled with T1 and type II cell marker Sp-C. E and F are higher magnifications of the areas  
in the white squares in C and D, respectively. G is the same section as in H, showing more examples of YFP+Sp-C cells in control lungs at 5 d after PA  
challenge. (M–P) Mutant (ROSA-YFP-EKO) lungs were infected with control virus (M and N) or adenovirus expressing FoxM1 (O and P). M and O were 
labeled with T1 and YFP, whereas N and P are the same section as in M and O, respectively, but labeled with T1 and Sp-C. Arrows denote clusters  
of cuboidal YFP+ cells expressing faint Sp-C in the FoxM1 virus–infected lungs (O and P). Data are representative of three independent observations.  
Bars: (A–D and I–P) 20 µm; (E–H) 10 µm.JEM Vol. 208, No. 7 
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At 96 h, the cell numbers were reduced to basal level in con-
trol but remained high in mutant lungs (Fig. 8 B). Hema3 
staining showed that most cells in control BAL were macro-
phages,  whereas  mostly  neutrophils  were  present  in  BAL 
from the mutant lungs (Fig. 8, C and D). Thus, the initial 
Next we determined whether expression of FoxM1 would 
induce type II cells to trans-differentiate into type I cell in the 
FoxM1 mutant. We i.t. injected adenovirus expressing FoxM1 
(Wang et al., 2002) in YFP-EKO mice. At 5 d after PA in-
fection, the YFP+ type II cell clusters frequently observed   
in FoxM1 adenovirus–injected lungs expressed significantly 
lower levels of Sp-C (Fig. 6, O and P), indicating partial 
trans-differentiation into type I cells. In contrast, in control 
virus–injected YFP-EKO lungs, no such clusters were ob-
served; rather, the YFP+ type II cells expressed high levels of 
Sp-C (Fig. 6, M and N). Thus, FoxM1 expression partially 
rescued the mutant phenotype of defective type II to type I 
cell trans-differentiation.
Next, we used an in vitro system using T1 and Aqp5 
(aquaporin 5) as type I cell markers (Ma et al., 2000) to fur-
ther address the mechanism of trans-differentiation of type II 
cells into type I cells. Type II cells were isolated at 72 h after 
infection from ROSA-YFP or ROSA-YFP-EKO lungs and 
cultured for 30 h. In ROSA-YFP culture, the majority of 
cells became flat type I–like cells and some expressed T1, 
whereas  the  majority  of  ROSA-YFP-EKO  type  II  cells   
remained cuboidal and did not express T1 (Fig. 7, A and B). 
To quantify the trans-differentiated cells, type II cells were 
isolated at 72 h after infection and processed for RT-PCR. We 
observed that both WT and mutant cells expressed similar 
levels of Aqp5. However, after these cells were cultured for 
30 h, type II cells from control mice trans-differentiated 
into type I cells and expressed higher levels of Aqp5, whereas 
the mutant cells expressed low levels of Aqp5 (Fig. 7 C), indi-
cating a defective trans-differentiation phenotype.
We have shown that -catenin is a transcriptional target 
of FoxM1 (Mirza et al., 2010) and may play an important role 
in the type II to type I cell trans-differentiation (Flozak et al., 
2010). Here we used real-time RT-PCR to examine the type II 
cell expression level of -catenin during trans-differentiation 
in WT and FoxM1 mutant type II cells. We observed that both 
WT and mutant type II cells expressed similar levels of -catenin 
before and at 72 h after PA. However, when the cells from the 
PA-infected lung were cultured for 30 h to induce trans-
differentiation, the expression of -catenin in the mutant was 
significantly lower than control (Fig. 7 D), suggesting that   
-catenin is a candidate downstream target of FoxM1 regulat-
ing type II to type I cell trans-differentiation.
To assess injury and repair of the alveolar barrier, bron-
choalveolar lavage (BAL) fluid was collected at 48 h, 96 h, 
and 5 d after PA injection. At 48 h, BAL protein concentra-
tion was elevated in both control and mutant, indicating that 
the degree of alveolar barrier leakiness was similar. At 96 h to 
5 d, the protein concentrations returned to basal level in 
control lungs but remained high in the mutant (Fig. 8 A), in-
dicating that the barrier function was largely restored in WT 
but remained defective in mutant lungs. We next examined 
the cells in BAL. At 48 h, total cell counts in both control 
and mutant sample were high (Fig. 8 B). Hema3 staining 
showed that most of these cells were neutrophils (unpub-
lished data), indicating increased inflammatory cell influx.   
Figure 7.  Defective trans-differentiation of FoxM1-deficient  
type II cells into type I cells in vitro. (A and B) Type II cells were isolated 
from WT (ROSA-YFP; A) and mutant (ROSA-YFP-EKO; B) lungs at 72 h 
after PA injection and cultured for 30 h (24–36 h) to allow trans- 
differentiation into type I cells. Cells were stained with antibody specific 
for T1. Data are representative of three independent observations.  
Bar, 10 µm. (C and D) Type II cells were isolated in non–PA-injected lungs 
(basal) as well as in lungs 72 h after PA injection of WT (+/TetO-Cre/ 
FOXM1EKO) and mutant (SPC-rtTA/TetO-Cre/FOXM1EKO) mice, and the 
relative expression of mRNA encoding the type I cell marker Aqp5 (C) and 
-catenin (D) was measured by real-time RT-PCR. In another experiment, 
type II cells were isolated from WT (+/TetO-Cre/FOXM1EKO) and mutant 
(SPC-rtTA/TetO-Cre/FOXM1EKO) lungs at 72 h after PA injection and cul-
tured for 30 h (24–36 h) to allow trans-differentiation into type I cells. 
RNA was then isolated from cultured cells for real-time RT-PCR analysis 
of Aqp5 (C) and -catenin (D) mRNA. Data are presented by mean ± SE  
(n = 3–5 mice for each group from three independent experiments;  
*, P < 0.05 vs. control; **, P = 0.01 vs. control).1480 FoxM1 facilitates repair of alveolar injury | Liu et al.
pulmonary innate immunity by interacting with pathogen-
derived  components  and  macrophages  (Sano  and  Kuroki, 
2005). Sp-A– or Sp-D–null mice manifested delayed micro-
bial clearance and overexpression of proinflammatory cyto-
kines (Sano and Kuroki, 2005). We observed by Western blot 
analysis that both Sp-A and Sp-D were expressed similarly in 
mutant and control lungs at 96 h after infection (Fig. 9, B and C). 
Measurement of the amount of these two proteins (quantified 
by measuring their signal intensity and normalized to -actin 
expression) showed that the relative expression of Sp-A was 
1.1 ± 0.3 in control and 0.8 ± 0.2 in the mutant. Relative ex-
pression of Sp-D was 0.5 ± 0.2 in control and 0.6 ± 0.2 in 
mutant (mean ± SE; n = 3 mice for each group from three 
independent experiments). Thus, expression of Sp-A and Sp-D 
in mutant lungs was the same range as control. Furthermore, 
expression of Sp-B also did not show a significant difference 
between control and mutant (Fig. 9 D), indicating that the se-
verity of injury and initial immune response in mutant lungs 
were similar to control. Thus, the prolonged alveolar barrier 
defect of mutant lungs is likely the result of a defective repair 
program secondary to deletion of FoxM1 rather than any dif-
ference in the severity of injury or inflammation.
DISCUSSION
We have identified in this study the fundamental importance 
of the transcription factor FoxM1 expressed in alveolar type II 
cells in the mechanism of alveolar epithelial barrier repair 
after PA-induced lung injury. We used PA because it induces 
alveolar  injury  similar  to  that  encountered  in  pneumonia 
(Gray and Kreger, 1979; Sadikot et al., 2006). We showed that 
type II cell–specific disruption of FoxM1 markedly delayed 
the recovery of alveolar barrier function as indicated by pro-
longed neutrophil influx and increased BAL protein concen-
tration. There was a persistent alveolar barrier defect in FoxM1 
responses were similar in WT and mutant lungs, whereas 
mutant lungs showed a prolonged inflammatory response in-
dicating an impaired recovery.
Similar initial inflammatory response in FoxM1 mutant  
and WT lungs induced by PA
Fig. 9 A shows that changes of MIP2 (macrophage inflamma-
tory protein 2) generation, a major cytokine involved in at-
tracting neutrophils (Kobayashi, 2008), during the course of 
injury and repair were similar in both WT and mutant lungs; 
both showed high concentrations of MIP2 at 48 h after PA 
and returned to basal levels at 96 h. We cultured lung lysates 
to examine bacterial colony growth because this could account 
for different rates of recovery. In both control and mutant, we 
did not observe growing bacteria colonies at 48 h after infec-
tion (n = 3 mice for each group from three independent ex-
periments), indicating that bacteria were cleared from lungs 
with similar efficiency in both groups.
Sp-A, Sp-B, and Sp-D are SAPs reported to be down-
stream targets of FoxM1 during fetal lung development (Kalin 
et al., 2008). Sp-A and Sp-D play a role in modulating 
Figure 8.  Failure of alveolar barrier repair after PA challenge  
in lungs with FoxM1 deleted in type II cells. (A and B) Protein concentra-
tion and cell number in BAL isolated from WT and mutant (SPC-rtTA/TetO-
Cre/FOXM1EKO) lungs. At 48 h and 96 h to 5 d after infection, protein 
concentrations (A) and cells (B) were measured in both samples. Data are 
from at least three independent experiments and are presented as mean ± 
SE (n = 3 mice for each group in B; n = 3 mice for each group for 0 h  
and 48 h in A). At 96 h to 5 d, the data were collected in three WT and 
three mutants at 96 h and two for each group at day 5 (*, P < 0.05 vs. 
control). (C and D) At 96 h after infection, cells from control (C) and mu-
tant (D) lungs were analyzed to distinguish monocytes and neutrophils. 
Data are representative of three independent observations. Bar, 20 µm.
Figure 9.  Similar inflammatory response of the FoxM1 mutant 
and control lungs. (A) MIP2 concentrations in WT and mutant (SPC-rtTA/
TetO-Cre/FOXM1EKO) lung lysates before (basal) and 48–96 h after PA 
infection. Data are presented as mean ± SE (n = 3 mice for each group 
from three independent experiments). (B–D) Protein expression of Sp-D (B), 
Sp-A (C), and Sp-B (D) in WT and mutant (Mut) lungs at 96 h after PA 
infection as assessed by Western blot analysis. Data are representative of 
three independent observations.JEM Vol. 208, No. 7 
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The FoxM1 mutant type II cells also showed defective 
trans-differentiation into type I cells in both in vitro and   
in vivo experiments. We surmised from this observation that 
FoxM1 regulates expression of genes involved in the forma-
tion of type I cells. Our results suggested that -catenin is a 
candidate target of FoxM1 regulating the type II to type I cell 
trans-differentiation, which is consistent with the evidence 
that FoxM1 binds to the promoter of -catenin and directly 
regulates -catenin expression (Mirza et al., 2010). -catenin   
is also involved in the mechanism of differentiation of vari-
ous cell types including lung cells (Mucenski et al., 2005;   
De Langhe and Reynolds, 2008; Grigoryan et al., 2008) and 
has been shown to play a key role in the type II to type I cell 
trans-differentiation (Flozak et al., 2010). Our result suggest 
that FoxM1 interacts with the Wnt/catenin signaling (Grigoryan 
et al., 2008) in regulation of type II to I cell trans-differentiation 
after injury.
Notably, FoxM1 expression in type II cells increased only 
during the early repair phase when a subpopulation of cells 
adopted a progenitor phenotype as indicated by their co-
expression of Sca-1. Given that Sca-1 is a marker of progenitor 
cells (Holmes and Stanford, 2007), these findings suggest that 
Sca-1+FoxM1+ type II cells represent the pool of regenerat-
ing type II cells. We found that Sca-1+ type II cells had a 
higher potential of trans-differentiation into type I cells in vitro 
than the Sca-1 counterpart (unpublished data). However, it 
is not clear whether the Sca-1+ type II cells appearing after 
PA are derived from expansion of an existing Sca-1+ popula-
tion or from reprogramming of quiescent Sca-1 type II cells. 
We found that in the type II cell–specific FoxM1 mutant 
mouse, although FoxM1/ type II cells showed impaired cell 
proliferation, these mutant lungs generated a relatively high 
ratio of Sca-1+ type II cells at 72 h after PA (40 ± 8% Sca-1+ 
among total type II cells; n = 4 mice in two independent ex-
periments), similar as WT lungs. Thus, it is unlikely that the 
Sca-1+ cells appearing at 72 h after PA are derived from an 
expansion of preexisting Sca-1+ cells. Furthermore, the per-
centage of Sca-1+ type II cells in the total type II cell popula-
tion can be as much as 60% after injury, further supporting 
the claim that they are derived from the reprogramming of 
quiescent Sca-1 type II cells. Some previous studies have 
also suggested a heterogeneity among type II cells; e.g., some 
type II cells expressed a lower level of E-cadherin than others 
(Reddy et al., 2004), whereas others expressed a relatively low 
level of CC10 (Kim et al., 2005b; Rawlins et al., 2009a). Thus, 
the type II cell subpopulation expressing higher amounts of 
both FoxM1 and Sca-1 may serve as progenitor cells respon-
sible for the proliferation and trans-differentiation of type II 
cells needed to regenerate the alveolar epithelial barrier after 
PA injury.
One might expect that adult type II cells after injury 
revert to a state resembling alveolar precursor cells during 
embryogenesis; however, we did not see any differences   
in expression of several transcription factors, Id2, Erm, Gata6, 
and Elf5, involved in alveolar development (Liu et al., 2003; 
Metzger et al., 2008; Zhang et al., 2008; Rawlins et al., 2009b). 
mutants caused by defective type II cell proliferation and 
trans-differentiation into type I cells.
Although type I cells comprise 95% of the alveolar 
surface area, studies have shown that type II cells mediate the 
regeneration of type I alveolar cells and restoration of barrier 
function after alveolar injury (Evans et al., 1973, 1975). Type II 
cells after injury thus function as progenitor cells because 
they can self-renew and trans-differentiate into type I cells 
(Evans et al., 1973, 1975; Mason, 2006; Sugahara et al., 2006). 
This specialized function of type II cells has been proposed to 
play a fundamental role in alveolar epithelial barrier repair 
(Rawlins and Hogan, 2006; Stripp, 2008). We focused in this 
study on the role of the transcription factor FoxM1 in regu-
lating the progenitor function of type II cells. FoxM1 expres-
sion was increased in type II cells only during the repair phase 
after PA injury. In contrast, expression of FoxM1 in type I cells 
did not increase during this period, suggesting that FoxM1 in 
type I cells does not participate in the repair. We observed that 
FoxM1 mutant type II cells had greatly reduced proliferation 
rates and severely impaired trans-differentiation into type I cells, 
resulting in a failed alveolar barrier repair program. These   
results provide the first evidence to our knowledge of the   
essential role of FoxM1 in type II cells in the mechanism of 
alveolar barrier repair.
Although the alveolar barrier defect observed in FoxM1 
mutant lungs indicates a defective repair, an alternative expla-
nation could be an enhanced inflammatory response in the 
mutant lungs. However, this is unlikely because the postinjury 
changes in MIP2 concentration, a marker of inflammation, 
were similar in FoxM1 mutant and WT lungs. The mutant 
lungs also cleared bacteria as rapidly as WT, thus precluding 
any differences in bacterial clearance and resulting lung in-
flammation as the basis for delayed alveolar epithelial barrier 
recovery seen in FoxM1 mutant lungs. A previous study 
showed that FoxM1 can regulate the expression of SAPs 
during embryogenesis (Kalin et al., 2008). The SAPs Sp-A 
and Sp-D in particular play a role in the lung’s immune re-
sponse (Sano and Kuroki, 2005). However, we observed that 
the mutant lungs exhibited the same levels of these proteins as 
WT, ruling out the role of SAPs in the delayed epithelial bar-
rier recovery response seen in FoxM1 mutant lungs.
Type II cell proliferation was increased in WT but not in 
FoxM1-deleted mice, indicating that FoxM1 was required for 
type II cell proliferation during repair. FoxM1 has been shown 
to regulate the expression of proteins involved in cell cycle 
progression (Costa et al., 2005). We observed that CDC25C 
and cyclin B1 were the likely FoxM1 downstream targets   
responsible for type II cell–mediated proliferation. A study has 
shown that FoxM1 disruption in the embryonic lung epithe-
lium did not affect the proliferation of alveolar precursor cells 
(Kalin et al., 2008), suggesting that FoxM1 does not play a 
role in mediating cell proliferation during lung development. 
However, in our study, we used an inducible system in which 
the FoxM1 gene was deleted in adult type II cells before in-
duction of lung injury, thus bypassing the known effects of 
FoxM1 in embryonic development.1482 FoxM1 facilitates repair of alveolar injury | Liu et al.
15 min at 250 g. Cells were then stained with hamster anti-T1 antibody 
(Developmental Studies Hybridoma Bank) and Cy3 or Cy5 secondary anti-
body (Jackson ImmunoResearch Laboratories, Inc.). T1+ cells were isolated 
by MoFlo high speed cell sorting performed at the Flow Cytometry Core at 
the University of Illinois at Chicago.
Real-time PCR. RNA was extracted by TRIZOL (Invitrogen), treated by 
DNase I (QIAGEN), and purified with an RNeasy kit (QIAGEN). Real-
time RT-PCR was performed using a Quanti-Tect SYBR Green RT-PCR 
kit (QIAGEN) and ABI Prism 7000 Sequence Detection System (Applied 
Biosystems). Primers are listed in Table S1; the primers for CDC25C, 
Cyclin B1, and -catenin were obtained from QIAGEN. Data were analyzed 
using the comparative C method. Relative quantification to the control 
sample calibrator was calculated using the formula 2(C). Gene expression 
was normalized to the level of cyclophilin (CLO) as an internal control 
(Zhao et al., 2002).
Flow cytometry. For fluorescent cell sorting of Sca-1+ and Sca-1 cells, 
freshly isolated type II cells were resuspended to 1.0 × 106 cell/ml in cold 
PBS/2% BSA, stained with PE- or APC-labeled rat anti–Sca-1 mAb as well 
as PE or APC-rat IgG2a isotype control (eBioscience) at 0.25 µg antibody 
per million cells for 50 min and washed by PBS/2% BSA. The cells were 
sorted with the MoFlo high speed cell sorter (BD) at the Flow Cytometry 
Service Core at the University of Illinois at Chicago. Cells were gated on 
forward and side scatter to exclude debris and cell clusters. Reanalysis of 
fluorescent profile after the sort showed that the purity of sorting is 99%. 
For sorting of YFP+ and YFP cells, freshly isolate type II cells were directly 
sorted with the MoFlo high speed cell sorter without staining.
For FACS phenotyping, freshly isolated type II cells were unfixed or 
fixed with 4% paraformaldehyde for 15 min at room temperature and perme-
abilized with 0.1% Triton X-100 in PBS for 10 min, and the treated cells were 
processed for antibody staining. For all experiments, isotype control and single 
color control were performed. The stained cells were sorted using a CyAn ADP 
flow cytometer (Beckman Coulter) located at the Flow Cytometry Service 
Core. The results were analyzed with Cytomation Summit 4.3 software.
Immunohistochemistry. The blood in lungs was washed out by perfusion 
with 10 ml PBS through the right ventricle. The lung was then inflated with 
2 ml of 4% paraformaldehyde/PBS i.t. and fixed in this solution at 4°C over-
night before proceeding to paraffin embedding and sectioning at the Histol-
ogy Core at the University of Illinois at Chicago. Hematoxylin and eosin 
(H&E) staining was also performed at the Histology Core. For preparing 
frozen sections, the lung was injected with 2 ml of 80% OCT/PBS i.t. and 
embedded in 100% OCT (Tissue Tek) and then quickly frozen in 70°C.   
7-µm sections were cut using a cryostat. In some experiments, freshly isolated 
type II cells were immobilized on Superfrost/Plus microscope slides (Thermo 
Fisher Scientific) by cytospin centrifugation and fixed with 4% parafor-
maldehyde/PBS for 30 min at room temperature.
For BrdU labeling, the mice were injected with BrdU (75 mg/kg body 
weight) by i.p. injection at 5 h before tissue collection unless otherwise speci-
fied in the Results section. Tissue was treated with citrate antigen unmask 
solution (Vector Laboratories) for 10 min at 95°C before proceeding to anti-
BrdU antibody staining. TUNEL (terminal deoxynucleotidyl transferase 
dUTP-biotin nick end labeling) assay was performed using the fluorescein in 
situ cell death detection kit (Roche) on frozen lung sections.
The following antibodies were used in this study: anti-BrdU (BD) was 
used at 1:3, anti–Sp-C (Millipore) was used at 1:1,000, and anti-GFP antibody 
(Aves Laboratories) was used at 1:500 for detecting YFP. The background 
for each ROSA-YFP mouse varied, but the signal of YFP+ type II cells 
was robust compared with background. mAb to T1 (used at 1:20) was   
obtained from the Developmental Studies Hybridoma Bank. Fluorescent 
secondary antibodies (Cy3, Alexa Fluor 488, or Cy5; Jackson Immuno-
Research Laboratories, Inc. or Invitrogen) were used at 1:200. Images were 
captured by a confocal microscope (LSM 510; Carl Zeiss) located at the Imag-
ing Core Facility at the Department of Pharmacology (University of Illinois   
Furthermore, FoxM1 was not required for proliferation of the 
embryonic lung epithelium (Kalin et al., 2008), whereas, as 
we have shown in this study, it is required for proliferation of 
adult type II cells during repair. Thus, the mechanism of trans-
differentiation of type II to type I cells during alveolar repair 
is different from differentiation from alveolar precursor cells 
into type II and I cells during embryogenesis.
In conclusion, we have identified FoxM1 in type II alveo-
lar epithelial cells as the key regulator of alveolar epithelial 
barrier repair through its ability to control proliferation and 
trans-differentiation into type I cells. As FoxM1 is the first 
transcription factor shown to regulate alveolar barrier repair, 
these findings raise the possibility of pharmacologically tar-
geting FoxM1 in type II cells to restore alveolar homeostasis 
after lung inflammatory injury in diseases such as acute respi-
ratory distress syndrome.
MATERIALS AND METHODS
Mice stain and PA injury model. The animal experiments were approved 
by the Animal Care Committee and Institutional Biosafety Committee of 
the University of Illinois at Chicago. The SPC-rtTA/TetO-Cre/FOXM1EKO 
mouse line, which carries transgenes for SPC-rtTA and TetO-Cre, is homozy-
gous for the FoxM1loxP locus and is in C57/FVB mixed genetic background 
(Kalin et al., 2008). This line was used for doxycycline-induced type II alveolar 
cell–specific deletion of the FoxM1 gene. In our study, mutant genotype   
refers to SPC-rtTA/TetO-Cre/FOXM1EKO, whereas control genotype refers 
to +/TetO-Cre/FOXM1EKO. Mice were fed with 1 mg/ml doxycycline in 
drinking water for 14 d and then in normal water for 1 wk before experiments. 
Each experiment was made with paired litter mates of mutant and control 
genotype of the same gender.
B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J mice were obtained from 
the  Jackson  Laboratory  and  were  crossed  with  SPC-rtTA/TetO-Cre/ 
FOXM1EKO mice to generate SPC-rtTA/TetO-Cre/ROSA26-YFP/+ and   
SPC-rtTA/TetO-Cre/ROSA26-YFP/FOXM1EKO mice. All mice were fed 
with doxycycline unless specified otherwise in the text.
PA (strain 103) was prepared as described previously (Sadikot et al., 
2006). Mice were challenged with 5 × 106 CFU PA via i.t. instillation.
Isolation and culture of type II cells. Type II cells were isolated as de-
scribed previously (Rice et al., 2002; Gobran and Rooney, 2004). In brief, the 
lung was first perfused by 10 ml PBS through the right ventricle to wash out 
the blood, and then 2 ml Dispase (BD) was injected i.t. and followed by 0.5 ml 
melted agarose (45°C). The cells were dissociated by Dispase and DNase I 
treatment and panned by tissue culture plates coated with anti-CD45 and 
anti-CD32 antibodies. The cells were then collected by centrifugation at 150 g 
for 6 min. The purity of type II cells was accessed by a modified Papanicolaou 
stain (Dobbs, 1990), and only preps with >90% purity were used for subse-
quent experiments.
To access the trans-differentiation into type I cells, type II cells were iso-
lated and cultured in tissue culture–treated plates (Corning). The cells were 
grown in DME with 15 mM Hepes, 10% FBS, penicillin/streptomycin, and 
glutamine for 24–48 h, and the cultured cells were processed for RNA isola-
tion or antibody staining.
Isolation of type I cells. Type I cells were isolated by elastase digestion as 
described previously (Chen et al., 2004; Gonzalez et al., 2009). Lungs were 
perfused through the pulmonary artery with PBS. 2 ml of solution D (RPMI 
1640 medium with 25 mM Hepes, pH 7.2) containing 10% dextran 40 and 
4.5 U/ml elastase (Worthington) was instilled i.t., and the lung was incubated 
at 37°C for 30 min. Cells were subsequently dissociated in solution D with 
20% FBS and 100 U/ml DNase I (Sigma-Aldrich) and centrifuged for   JEM Vol. 208, No. 7 
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at Chicago). The images were captured at room temperature using a 63× NA 
1.2 objective lens mediated by water, except in Figs. S1 (A and B) and S3   
(A and B), in which 20× lenses were used to show more cells in one image 
window. The images were captured and processed using LSM 510 software 
(Carl Zeiss). Single images were acquired, and no operations such as decon-
volution, 3D reconstitutions, or surface or volume rendering were performed. 
Fig. S1 (D and E) was captured using a 10× lens and an imaging system 
(Axioplan-2; Carl Zeiss). Fig. 5 (I and J) was captured using a 20× lens and 
an Axioplan-2 imaging system.
Adenovirus production and infection. A replication-defective E1- and 
E3-negative adenovirus expressing human FoxM1B, AdFoxM1, was con-
structed as described previously using standard overlap recombination (Wang 
et al., 2002). This recombinant virus was twice plaque purified, and adeno-
virus particles were purified from 293 cell lysate by CsCl centrifugation and 
dialyzed to remove the CsCl as described previously (Wang et al., 2002). The 
second recombinant virus, AdFoxM1B-TA, lacks the terminal 60 aa (689–
748), which coincide with the transcriptional activation domain of the protein 
and the protein encoded fails to activate a transcriptional reporter fused to   
6 multimers of the FoxM1/FoxA binding motif (Wierstra and Alves, 2006). 
The recombinant virus, AdHCMVap1LacZ, containing the -galactosidase 
reporter gene, was a gift from F. Graham (McMaster University, Hamilton, 
Ontario,  Canada;  Graham  and  van  der  Eb,  1973). AdFoxM1B-TA  or   
AdHCMVap1LacZ was used as control. For infection of cultured type II 
cells, the adenovirus particles were incubated with cells in serum-free media 
for 40 min at room temperature, with a multiplicity of infection of 20. For   
in vivo infection of the virus in lungs, 5 × 108 PFU virus in PBS were in-
jected i.t. at 3 d before PA injection.
BAL analysis. BAL fluid was collected as described previously (Sadikot   
et al., 2006). Approximately 1 ml BAL was collected for each mouse, and 
protein concentration was determined using the Micro BCA protein assay kit 
(Thermo Fisher Scientific). Cells in BAL were quantified using a hemo-
cytometer. Cells were immobilized on Superfrost/Plus microscope slides by 
cytospin centrifugation and further stained using a Hema3 staining kit as   
described previously (Sadikot et al., 2006).
Western analysis and cytokine quantification. Lung lysates were col-
lected as described previously (Zhao et al., 2006), and protein concentration 
was determined using the Micro BCA protein assay kit. 50 µg of total protein 
was loaded in each lane for Western blot analysis. The following primary anti-
bodies were used: anti–Sp-A, anti–Sp-B, and anti–Sp-D (Millipore) at 1:1,000. 
Antiactin (Santa Cruz Biotechnology, Inc.) was used as loading control. Protein 
quantification was further determined by measuring the intensity of the signal in 
Western blot films using the ImageJ program (National Institutes of Health).
MIP2 levels in lung lysates were measured using the Quantikine mouse 
CXCL2/MIP2 Immunoassay kit (R&D Systems). 25 µl of lysates was used 
for each sample, and the concentration of cytokines was normalized to the 
total protein amount.
Statistics. Differences between groups were examined for statistical signifi-
cance using the Student’s t test. P < 0.05 denoted the presence of a statisti-
cally significant difference.
Online supplemental material. Fig. S1 shows additional analysis of the 
PA lung injury model. Fig. S2 shows the expression level of several genes 
in type II cells from PA-challenged lungs. Fig. S3 shows additional analy-
sis  of  the  SPC-rtTA/TetO-Cre/ROSA-YFP/+  (ROSA-YFP)  mouse  line. 
Table S1 shows the sequences of the primers for RT-PCR used in this 
study. Online supplemental material is available at http://www.jem.org/cgi/ 
content/full/jem.20102041/DC1.
We thank the Flow Cytometry Service Core at the University of Illinois at Chicago 
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